• Apolipoprotein B (ApoB)-guided therapy produced the greatest quality-adjusted life-year gains.
• ApoB strategy was cost-effective ($30,300/quality-adjusted life-year).
• Non–high-density lipoprotein cholesterol modestly improved outcomes vs low-density lipoprotein cholesterol at lower cost.
• ApoB was optimal in 65% of probabilistic analyses.
• Higher costs reflected longer survival and extended treatment duration.

Source: JAMA